Theratechnologies Inc.

225 articles with Theratechnologies Inc.

• Theratechnologies Hires Vice President, Human Resources

  5/31/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Mr. André Dupras is joining the Company as Vice President, Human Resources.

• Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Experience With Trogarzo®

  5/20/2021

  Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported on positive results presented in two separate posters in conjunction with ACTHIV 2021 virtual conference being held May 20-22, 2021.

• Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021

  5/18/2021

  heratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer will participate in a virtual fireside chat hosted by Edward Nash at Canaccord Genuity on Thursday, May 20, 2021 at 2:00 p.m. ET.

• Announcements in Conjunction With Theratechnologies Annual Meeting - May 13, 2021

  5/13/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, held its annual meeting of shareholders.

• Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights

  4/14/2021

  Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter ended February 28, 2021 (Q1 Fiscal 2021).

• Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference

  4/12/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer will present at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 10:30 a.m. ET.     

• Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer TypesTH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone

  4/10/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association for Cancer Research.

• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.

• Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors

  3/24/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors.

• Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver InflammationData presented at ENDO 2021

  3/20/2021

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of tesamorelin on the circulation of immune activation markers associated with liver inflammation, was presented at The Endocrine Society’s annual meeting, ENDO 2021.

• Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference

  2/25/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually March 9 – 10, 2021.

• Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial ResultsRecord Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively

  2/25/2021

  Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced its financial results for the fourth quarter and its fiscal year ended November 30, 2020 (Fiscal 2020).

• Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020

  2/11/2021

  Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2020 on Thursday, February 25, 2021. A conference call will be held on February 25, 2021 at 8:30 a.m. (ET) to discuss the results.

• Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers

  2/4/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

• Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

  1/14/2021

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology Investor Conference on Wednesday, January 20, 2021 at 3:30 p.m. ET.      To access t

• 

  BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

  1/14/2021

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
• 

  Clinical Catch-Up: January 4-8

  1/11/2021

  The new year began with a fairly low level of clinical trial news. Here’s a look.

• Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities

  1/7/2021

  Expects record Q4 and FY 2020 revenues Receives ‘Study May Proceed’ letters from FDA for Phase 3 trial of tesamorelin in NASH and Phase 1 trial of TH1902 in various cancers

• 

  Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

  12/10/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers

  12/8/2020

  I n addition to ovarian and triple-negative breast cancers , TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers IND-enabling toxicity study concludes that TH1902 can be administered at 3 times the maximum tolerated dose of docetaxel alone S ignificant potential to improve therapeutic window